Want to see IN:AJANTPHARM full AI Analyst Report?
AJANTPHARM Stock Chart & Stats
₹3366.45
₹16.60(0.49%)
At close: 4:00 PM EDT
₹3366.45
₹16.60(0.49%)
Day’s Range― - ―
52-Week Range₹2,335.00 - ₹3,598.40
Previous CloseN/A
Volume81.90K
Average Volume (3M)2.10K
Market Cap
₹433.54B
Enterprise Value₹346.33K
Total Cash (Recent Filing)₹6.65B
Total Debt (Recent Filing)₹2.60B
Price to Earnings (P/E)38.1
Beta0.40
Next Earnings
Nov 04, 2026EPS Estimate
23.05Next Dividend Ex-DateN/A
Dividend Yield0.81%
Share Statistics
EPS (TTM)84.53
Shares Outstanding124,935,620
10 Day Avg. Volume2,991
30 Day Avg. Volume2,099
Financial Highlights & Ratios
PEG Ratio2.23
Price to Book (P/B)7.74
Price to Sales (P/S)6.43
P/FCF Ratio231.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)98.72
Revenue Forecast (FY)₹62.83B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetAjanta's low leverage and conservative balance sheet provide durable financial flexibility, allowing the company to fund capex, product registrations, and geographic expansion without needing frequent external capital. Consistent equity growth and strong ROE support long-term capital allocation and resilience through industry cycles.
Steady Revenue Growth And Geographic/therapeutic DiversificationSustained top-line growth and a diversified portfolio across ophthalmology, dermatology, cardiology and international markets reduce dependence on any single product or region. This structural diversification supports stable demand, aids new product rollouts, and underpins multi-quarter growth visibility for 2-6 month horizons.
Strong Profitability And ROEHealthy margins and elevated ROE indicate durable pricing power and efficient operations across branded generics and specialty segments. Sustained profitability enables internal funding for marketing and product development, supports reinvestment into higher-growth therapies, and strengthens long-term shareholder returns.
Bears Say
Weakened Cash Conversion / FCF VolatilityOperating cash flow and free cash flow weakening despite profit growth suggests working-capital swings or higher cash investments. Less predictable cash conversion constrains capacity to sustainably fund dividends, buybacks, or opportunistic M&A, and raises financing sensitivity over the coming months.
Margin Compression In FY2026A material decline in gross and net margins may reflect adverse mix, pricing pressure, or cost inflation. If structural, margin erosion can reduce operating cash generation and weaken reinvestment capacity, requiring management actions to restore unit economics and sustain long-term profitability.
Uptick In Debt (watch Item)While overall leverage remains modest, the recent rise in debt is a structural risk if the trend continues. Increasing debt levels would raise interest obligations and reduce flexibility for R&D and international expansion, potentially forcing trade-offs in capital allocation over the next several quarters.
Ajanta Pharma Limited News
AJANTPHARM FAQ
What was Ajanta Pharma Limited’s price range in the past 12 months?
Ajanta Pharma Limited lowest stock price was ₹2335.00 and its highest was ₹3598.40 in the past 12 months.
What is Ajanta Pharma Limited’s market cap?
Ajanta Pharma Limited’s market cap is ₹433.54B.
When is Ajanta Pharma Limited’s upcoming earnings report date?
Ajanta Pharma Limited’s upcoming earnings report date is Nov 04, 2026 which is in 86 days.
How were Ajanta Pharma Limited’s earnings last quarter?
Ajanta Pharma Limited released its earnings results on Jul 30, 2026. The company reported ₹26.72 earnings per share for the quarter, beating the consensus estimate of ₹23.04 by ₹3.68.
Is Ajanta Pharma Limited overvalued?
According to Wall Street analysts Ajanta Pharma Limited’s price is currently Overvalued.
Does Ajanta Pharma Limited pay dividends?
Ajanta Pharma Limited pays a Annually dividend of ₹32 which represents an annual dividend yield of 0.81%. See more information on Ajanta Pharma Limited dividends here
What is Ajanta Pharma Limited’s EPS estimate?
Ajanta Pharma Limited’s EPS estimate is 23.05.
How many shares outstanding does Ajanta Pharma Limited have?
Ajanta Pharma Limited has 124,935,620 shares outstanding.
What happened to Ajanta Pharma Limited’s price movement after its last earnings report?
Ajanta Pharma Limited reported an EPS of ₹26.72 in its last earnings report, beating expectations of ₹23.04. Following the earnings report the stock price went up 0.935%.
Which hedge fund is a major shareholder of Ajanta Pharma Limited?
Currently, no hedge funds are holding shares in IN:AJANTPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ajanta Pharma Limited
Established in 1973 and headquartered in Mumbai, India, Ajanta Pharma Limited operates as a specialized pharmaceutical enterprise. This company, along with its subsidiaries, is dedicated to the development, manufacturing, and commercialization of finished dosage forms. Its extensive product range caters to numerous therapeutic categories, such as anti-infectives (antibiotic, anti-malarial), chronic disease management (anti-diabetic, cardiology), women's health (gynecology), pediatrics, respiratory ailments, general health, dermatology, ophthalmology, and pain management. Notable products include multivitamins, antibiotics, eye drops, and cough syrups. Ajanta Pharma boasts a substantial international footprint, operating across India, Africa, other parts of Asia, the United States, and additional global markets. Furthermore, it supplies its pharmaceutical offerings to various government entities, including armed forces, public hospitals, and governmental procurement departments.
Technical Analysis
Emcure Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―
―
Wockhardt Limited
―